Celgene International (CELG) Receives Approval from European Commission for the Treatment of Small Cell Lung Cancer
The European Commission (EC) today announced that Celgene’s amrubicin hydrochloride has been designated as an orphan medicinal product for the treatment of small cell lung cancer. This follows the European Medicines Agency's (EMEA) favorable opinion, issued by the EMEA's Committee for Orphan Medicinal Products (COMP). Amrubicin hydrochloride, a third generation drug, has already received approval and is now marketed in Japan for the treatment of both small cell lung cancer and non-small cell lung cancer by Nippon Kayaku. This official designation of amrubicin is important for Celgene because, once the designation is granted by the EC, it provides special incentives…